Unfortunately, the failure of trials including anti-PD1 mAbs (even if some interesting results have been observed from IMiDs-anti-PD1 combinatory strategies) revealed a dismal clinical role for the axis PDL1-PD1 in MM [61,62,63]. This evidence concerns the gene PDCD1 and Miyoshi myopathy.